42 related articles for article (PubMed ID: 20596604)
1. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.
Li X; Jia Z; Shen Y; Ichikawa H; Jarvik J; Nagele RG; Goldberg GS
Cancer Sci; 2008 Jul; 99(7):1326-33. PubMed ID: 18422756
[TBL] [Abstract][Full Text] [Related]
2. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.
Zhao Y; Guo S; Sun J; Huang Z; Zhu T; Zhang H; Gu J; He Y; Wang W; Ma K; Wang J; Yu J
PLoS One; 2012; 7(4):e35175. PubMed ID: 22529986
[TBL] [Abstract][Full Text] [Related]
3. The role of FHL1 in tumors.
Zeng Q; Jiang T
Gene; 2024 Jun; 911():148347. PubMed ID: 38458365
[No Abstract] [Full Text] [Related]
4. Correction to: Low FHL1 expression indicates a good prognosis and drug sensitivity in ovarian cancer.
Chen X; Yu Y; Su Y; Shi L; Xie S; Hong Y; Liu X; Yin F
Funct Integr Genomics; 2024 May; 24(3):96. PubMed ID: 38740604
[No Abstract] [Full Text] [Related]
5. Low FHL1 expression indicates a good prognosis and drug sensitivity in ovarian cancer.
Chen X; Yu Y; Su Y; Shi L; Xie S; Hong Y; Liu X; Yin F
Funct Integr Genomics; 2024 Feb; 24(1):25. PubMed ID: 38324167
[TBL] [Abstract][Full Text] [Related]
6. FHL1 Inhibits the Progression of Colorectal Cancer by Regulating the Wnt/β-Catenin Signaling Pathway.
Liu Y; Wang C; Cheng P; Zhang S; Zhou W; Xu Y; Xu H; Ji G
J Cancer; 2021; 12(17):5345-5354. PubMed ID: 34335951
[No Abstract] [Full Text] [Related]
7. DNA Methylation as a Therapeutic Target for Bladder Cancer.
Nunes SP; Henrique R; Jerónimo C; Paramio JM
Cells; 2020 Aug; 9(8):. PubMed ID: 32784599
[TBL] [Abstract][Full Text] [Related]
8. Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.
Wei X; Zhang H
Cancer Biol Med; 2020 May; 17(2):270-281. PubMed ID: 32587768
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling.
Li SZ; Hu YY; Zhao JL; Zang J; Fei Z; Han H; Qin HY
Oncol Lett; 2020 Jun; 19(6):3781-3788. PubMed ID: 32382330
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of quantitative proteome and transcriptional profiles reveals abnormal gene expression and signal pathway in bladder cancer.
Liao S; Ou M; Lai L; Lin H; Zou Y; Yu Y; Li X; Dai Y; Sui W
Genes Genomics; 2019 Dec; 41(12):1493-1503. PubMed ID: 31576517
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.
Zhang S; Zheng C; Yao S; Wang Z; Xu L; Yang R; Meng X; Wu J; Zhou L; Sun Z
PLoS One; 2018; 13(10):e0206139. PubMed ID: 30379883
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer.
Wang J; Huang F; Huang J; Kong J; Liu S; Jin J
Oncol Lett; 2017 Nov; 14(5):6109-6116. PubMed ID: 29113254
[TBL] [Abstract][Full Text] [Related]
13. X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.
Cao W; Liu J; Xia R; Lin L; Wang X; Xiao M; Zhang C; Li J; Ji T; Chen W
Oncotarget; 2016 Mar; 7(12):14537-50. PubMed ID: 26908444
[TBL] [Abstract][Full Text] [Related]
14. MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism.
Wang Y; Fu J; Jiang M; Zhang X; Cheng L; Xu X; Fan Z; Zhang J; Ye Q; Song H
PLoS One; 2014; 9(10):e108708. PubMed ID: 25272045
[TBL] [Abstract][Full Text] [Related]
15. Fhl1 as a downstream target of Wnt signaling to promote myogenesis of C2C12 cells.
Lee JY; Chien IC; Lin WY; Wu SM; Wei BH; Lee YE; Lee HH
Mol Cell Biochem; 2012 Jun; 365(1-2):251-62. PubMed ID: 22367176
[TBL] [Abstract][Full Text] [Related]
16. Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer.
Xu Y; Liu Z; Guo K
Mol Cell Biochem; 2012 Apr; 363(1-2):93-9. PubMed ID: 22143536
[TBL] [Abstract][Full Text] [Related]
17. Identification of common differentially expressed genes in urinary bladder cancer.
Zaravinos A; Lambrou GI; Boulalas I; Delakas D; Spandidos DA
PLoS One; 2011 Apr; 6(4):e18135. PubMed ID: 21483740
[TBL] [Abstract][Full Text] [Related]
18. CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer.
Matsumoto M; Kawakami K; Enokida H; Toki K; Matsuda R; Chiyomaru T; Nishiyama K; Kawahara K; Seki N; Nakagawa M
Int J Mol Med; 2010 Aug; 26(2):241-7. PubMed ID: 20596604
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
